Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine Plus Bevacizumab in Platinum-Resistant Ovarian Cancer
NCT01131039Phase 2Withdrawn
- Sponsor
- Emory University
- Start
- Jan 2011
- Primary completion
- Sep 2011
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by Emory University. Primary endpoint: Progression-free survival at 2 years. Planned start Jan 2011; status: withdrawn.
02
Drugs
bevacizumab
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT01131039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01131039.